Additional research on metabolic phenotypes may elucidate distinct obesity subtypes (e.g., insulin resistance, dyslipidemia, or chronic inflammation) that may derive differential benefits from GLP-1 receptor agonist therapy. Here, GLP1R is linked to Insulin resistance.